<DOC>
	<DOCNO>NCT00227747</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving radiation therapy together combination chemotherapy surgery may shrink tumor remove . It yet know whether give radiation therapy together capecitabine effective without oxaliplatin surgery treat rectal cancer . PURPOSE : This randomized phase III trial study radiation therapy , capecitabine , oxaliplatin see well work compare radiation therapy capecitabine treat patient undergo surgery stage II stage III rectal cancer .</brief_summary>
	<brief_title>Radiation Therapy Capecitabine With Without Oxaliplatin Treating Patients Who Are Undergoing Surgery Stage II Stage III Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy neoadjuvant chemoradiotherapy comprise radiotherapy capecitabine v without oxaliplatin follow total mesorectal excision , term rate complete surgical resection , patient resectable stage II III rectal cancer . Secondary - Compare overall disease-free survival patient treat regimen . - Compare clinical tumor response patient treat regimen . - Compare acute late toxicity regimens patient . - Determine biological parameter predict tumor response treatment-related toxicity patient treat regimen . - Compare sphincter preservation function patient treat regimen . OUTLINE : This randomize , control , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo radiotherapy daily 5 day week receive capecitabine daily 5 day week week 1-5 . - Arm II : Patient undergo radiotherapy receive capecitabine arm I . Patients also receive oxaliplatin weekly week 1-5 . All patient undergo total mesorectal excision 6 week completion chemoradiotherapy . PROJECTED ACCRUAL : A total 590 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma rectum T34 , N02 , M0 disease endorectal ultrasound T2 disease locate low rectum allow provide low pole ≤ 6 cm anal verge Tumor must accessible digital rectal examination ( i.e. , tumor locate low midrectum ) Resectable disease treatable chemoradiotherapy No unresectable disease ( i.e. , T4 disease high risk incomplete gross resection [ i.e. , R2 ] ) PATIENT CHARACTERISTICS : Age 18 80 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin &gt; 10 g/dL Hepatic Alkaline phosphatase normal Bilirubin normal Renal Creatinine ≤ 130 μmol/L No severe renal insufficiency Cardiovascular No cardiac insufficiency No symptomatic coronary artery disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No contraindication study treatment Prior acute intestinal obstruction allow provided patient underwent surgical diversion stoma No history cancer except basal cell skin cancer carcinoma situ cervix No peripheral neuropathy No uncontrolled diabetes No uncontrolled severe disease No geographical , social , psychological condition would preclude study followup PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy cancer No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy cancer Surgery Not specify Other No concurrent phenytoin No concurrent participation another clinical trial experimental medical treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
</DOC>